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Condensed abstract 
Systemic inflammatory response to cardiac surgery is a known trigger for postoperative atrial 
fibrillation. Latent predisposing factors may reside at the protein level. Proteins released by 
the epicardial adipose tissue preceding the development of postoperative atrial fibrillation 
were examined in order to explore possible mechanistic links in its pathogenesis. 
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What’s New 
x We present the first proteomics study to describe the EAT secretome  
x We characterised EAT proteins as a possible substrate for the development of POAF 
x Various proteins were differentially expressed in the EAT secretome in patient who 
later developed POAF 
x Amongst those gelsolin, involved in inflammation and ion channel regulation, was 
associated with the maintenance of sinus rhythm. 
x Understanding the role of EAT may offer novel insights into prevention and treatment 
of AF. 
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Introduction 
Atrial fibrillation (AF) is the most common postoperative arrhythmia following cardiac 
surgery affecting more than one third of patients and is associated with increased morbidity 
and mortality, prolonged hospitalisation, and increased costs.1 The genesis of postoperative 
AF (POAF) is multifactorial including predisposing factors and acute triggering events such 
as operative trauma and myocardial ischaemia, electrolyte imbalances, inflammation and 
oxidative stress.  
Epicardial Adipose Tissue (EAT) is a type of specialised visceral fat distributed mainly 
around the atrioventricular and interventricular grooves and along the coronary arteries; 
smaller amount is also seen on the atrial appendages  
Hatem and colleagues highlight how the abundance of EAT is associated with AF. They 
suggest EAT could exert a paracrine activity onto the myocardium by producing a large 
variety of bioactive substances (adipokines) with both proinflammatory and antinflammatory 
properties.2 Furthermore infiltrates of EAT are seen deep in the myocardium which could 
trigger arrhythmias by altering propagation of the depolarizing wave, and via remodelling of 
the atrial myocardium.3 
To date, the relationship between EAT proteome and the development of POAF has not been 
investigated.  
Salgado-Somoza et al conducted to date the only proteomic study of the EAT. They compared 
EAT and subcutaneous adipose tissue (SAT) in patients undergoing heart surgery with 2D-
DIGE and mass spectrometry. They found that proteins related to oxidative stress appeared to 
be more expressed in EAT rather than SAT in patients with coronary artery disease. They 
conclude that EAT is exposed to greater oxidative stress compared to SAT in patients with 
cardiovascular disease suggesting its possible association with myocardial stress.4 
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The proteome is the determinant of the cell phenotype and its variations are translated into 
changes in the cell and tissue functions. Unlike the genome, the proteome is much closer to 
the disease phenotype and can better elucidate the processes behind the manifestation and 
progression of disease. Proteomics investigates the proteome via different advanced 
techniques such as two-dimensional difference in-gel electrophoresis (2D-DIGE) and high 
performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). Our aim 
was to evaluate the EAT secretome and investigate substrate changes that precede AF and that 
may contribute to its genesis following cardiac surgery. 
 
 
Methods 
Patients 
EAT samples were collected from 76 consecutive patients, 50 for proteomic analysis and 26 
for gene expression studies. All patients were undergoing first time isolated coronary artery 
bypass graft surgery (CABG) with no history of AF, no antiarrhythmic therapy other than 
beta blockers and no immunomodulating therapy. Standardised anaesthetic, perfusion, and 
surgical protocols were followed. All patients underwent on-pump CABG at 35C.  All 
patients received beta blockers on the first post-operative day, unless contraindicated due to 
allergy, severe bradycardia or hypotension. No other specific therapy was adopted for 
prevention of POAF. Routine postoperative heart rhythm assessment was achieved with 
continuous telemonitoring for 48 hours after surgery and 3-hourly clinical examinations 
thereafter. Twelve-lead electrocardiograms were also assessed on day 0, 2 and 4 after surgery. 
Amiodarone, intravenous or oral after appropriate loading, was the treatment of choice in 
patients who developed AF. 
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Statistical Analysis 
Statistical analyses were performed using Prism version 6.0 and Microsoft Excel 2013 
software. The unpaired Student's t-test was used to assess statistical significance between 
normally distributed data; nominal variables were compared using the Fisher's exact test of 
independence. Statistical difference was indicated by a P value of <0.05. Data are expressed 
as mean ± SEM or mean ± STDEV as specified. 
Tissue Sampling and Preparation 
EAT tissue was obtained before establishing cardiopulmonary bypass (CPB) in order to avoid 
confounding factors generated by the exposure of blood to foreign material, in particular the 
initiation of inflammatory response of CPB. Approximately 500 mg of EAT was harvested, 
most commonly from the right ventricle. Samples for proteomic analysis of the secretome 
where finely minced and immediately incubated in 1-2 ml of high glucose serum free 
condition medium (DMEM, High Glucose, GlutaMAX™, Invitrogen), depending on sample 
size, enriched with insulin (Insulin human - recombinant, expressed in yeast, Sigma I2643) 
for 24 hours at 37° C and controlled 5% CO2 in order to stimulate adipokine production by 
the adipocyte and secretome release. Condition medium was utilised for 2D-DIGE of the 
secretome whereas the remaining fat tissue was subsequently used for protein extraction and 
western blot validations. 
26 samples were stored in RNA extraction solution (Quiazol, Qiagen), two were later 
discarded as not suitable for analysis, the remaining 24 were subsequently analysed for gene 
expression. 
 
EAT protein extraction: RIPA buffer (RadioImmuno Precipitation Assay buffer, ab156034, 
MitoSciences, abcam) supplemented with protease inhibitors was used to extract proteins 
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from approximately 100 mg of EAT. Protein concentration was determined by RC DC™, 
Bio-Rad.  
 
Two-dimensional difference in-gel electrophoresis (2D-DIGE): 10 vs. 10 protein samples 
from each group were analysed.  Prior to proteomic analysis, samples were purified using a 
commercial cleanup kit (ReadyPrep™ 2-D Cleanup Kit Bio Rad), urea and non-ionic 
detergents were used to unfold proteins and protease inhibitors where added. Proteins were 
then resuspended in DIGE lysis buffer (8M urea, 4% w/v CHAPS, 30 mM trisCl, pH  8.5). 
Protein concentration was measured with Bradford assay methodology (Bio-Rad). 
After clean-up, proteins were redissolved in DIGE lysis buffer (8M urea, 4% w/v CHAPS, 
30mM Tris-HCl, pH 8.5).  
Randomised labeling was applied. 50µg proteins per each sample from a given pair (i.e. 
POAF and SR group) were randomly labelled with Cy3 or Cy5 fluorescent dye (CyDye, GE 
Healthcare). Additionally a pooled internal standard was created by mixing the same amount 
of all samples and labelled with Cy2. Paired samples and internal standard (biological 
replicate) were run on every gel effectively creating a technical replicate to normalize against, 
enabling to distinguish biological “real” variation from technical variation. 
After protein labelling the same protein amount of two different paired samples and internal 
standard, were mixed. 2x DIGE buffer (8M urea, 4% w/v CHAPS, 2% w/v DTT, 2% v/v 
Pharmalyte pH 3-10) and rehydration buffer (8M urea, 0.5% w/v CHAPS, 0.2% w/v DTT, 
0.2% w/v Pharmalyte pH 3-10 and trace Bromophenol blue) were added to the mixed sample 
to a final volume of 450 µl. The samples were loaded on IPG strips (18cm, pH 3-10 nonlinear, 
GE healthcare). The isoelectric focusing (IEF) was carried out at 0.05mA/strip for 28 kVh at 
20◦C after overnight rehydration.  For the second dimension large format 12% Tris-Glycine 
gels were casted, IPG strips paced on top of the gels and sodium dodecylsulphate 
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polyacrylamide gel electrophoresis (SDS-PAGE) was run at 16W/gel until blue dye front had 
migrated off the end of the gel. Subsequently protein spots were visualized by fluorescence 
scanner (Ettan DIGE Imager, GE health care).  
Silver staining (PlusOne silver staining kit, GE healthcare) of the gels allowed later 
visualisation of the corresponding protein spots for manual spot picking. In order to analyse 
differentially expressed proteins in the two sample groups, specialised software was used 
(DeCyder 7.0, GE Healthcare). A pick list of differentially expressed proteins (p<0.05, ratio ≥ 
1.2 or ratio ≤ -1.2) was generated and spots manually picked. 
Liquid Chromatography Tandem Mass spectrometry (LC-MS/MS): In-gel digestion with 
trypsin was performed according to published methods modified for use with an Investigator 
ProGest (Digilab) robotic digestion system.5 After tryptic digestion, peptides were separated 
on a reverse-phase nanoflow HPLC system (Dionex UltiMate 3000 RSLCnano). The column 
(Acclaim PepMap100, 75 µm x 25 cm, 3 µm, 100Å, Thermo Fisher Scientific) was coupled to 
a nano spray source (Picoview) directly connected to LTQ Orbitrap XL mass spectrometer 
(Thermo Fisher Scientific). Spectra were collected using full MS scan mode with orbitrap 
over the mass-to-charge (m/z) range 350–1600 followed by 6 data-dependent MS2 scan. 
Extract_msn.exe was used to generate MS/MS peak lists that were matched to a human 
database (UniProtKB/Swiss-Prot Release 2013_08, 20,267 protein entries) using Mascot 
2.3.01 (Matrix science). The following parameters were used: parent mass tolerance 10ppm, 
fragment mass tolerance 0.8Da, carbamidomethylation on cysteine as fixed modification and 
oxidation on methionine as variable modification, 2 missed cleavages were allowed. Scaffold 
(version 4.3.2, Proteome Software Inc.) was used to validate MS/MS-based peptide and 
protein identifications. Peptide identifications were accepted if they could be established at 
greater than 95.0% probability as specified by the Peptide Prophet algorithm. Protein 
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identifications were accepted if they could be established at greater than 99.0% probability 
and with at least 2 peptides.  
 
Western blotting: validations were performed by western blotting on 6 vs. 6 EAT protein 
extracts samples. 12 μg of proteins were loaded with sample buffer and separated on Bis-Tris 
4% to 12% polyacrylamide gradient gels (NuPage, Life-Technologies) using SDS running 
buffer (NuPAGE Mops SDS Running Buffer, Invitrogen) at 130V constant voltage. The gel 
was sandwiched with a nitrocellulose blotting membrane (GE healthcare life sciences) and 
proteins transferred to it applying a constant electrical current at 350mA in transfer buffer 
(Tris Base 25 mM, Glycine 200mM, 20% methanol) for 2.5 hours. Membranes were blocked 
in 5% milk-PBST, probed overnight at 4°C with anti-gelsolin antibody (1:1000, rabbit 
polyclonal, ab74420, abcam) and subsequently incubated in species-specific secondary 
antibodies (Dako). Enhanced chemiluminescence (ECL; GE Healthcare) was applied to the 
membranes and X-ray films exposed into cassettes. Films were developed using Kodak 
automated x-ray film developer. 
 
RNA extraction: 26 samples were prepared for qPCR. Total RNA was isolated from samples 
weighing 80 to 150 mg previously stored in 700 μl  of QIAzol Lysis Reagent using miRNeasy 
Mini Kit (QIAGEN®) as per manufacturer’s instructions. Total recovered RNA was eluted in 
25 μl of nuclease free H2O. RNA concentration and purity were evaluated by using NanoDrop 
1000 spectrophotometer (Thermo Fisher Scientific). In two samples RNA quality was found 
to be suboptimal, the remaining 24 samples were later utilised for analysis. 
 
Reverse transcription (RT): 400 ng of RNA were reversed transcribed into cDNA using the 
High Capacity Reverse Transcriptase kit (Life Technologies) according to manufacturer 
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instructions. RT-PCR reaction program was set as follows: samples were initially denatured at 
25°C for 5 minutes, then reverse transcribed for 90 minutes at 42°C, and finally the reverse 
transcriptase enzyme was inactivated for 15 minutes at 72°C. Samples were then diluted to 
10ng/μl using RNase free water. 
 
qPCR: gene expression study was performed via qPCR using TaqMan assay for gelsolin 
gene (Life technologies Hs00609272_m1). SP1 (Specificity Protein 1) was used as a 
normalization control. The PCR plate was loaded with 2.25 μl of RT product and qPCR was 
performed on Viia7 system thermocycler (Thermo Fisher Scientific). Programme was set at 
50ºC for 2 min, 95ºC for 10 min, followed by 40 cycles of 95ºC for 15 sec and 60ºC for 1 
min. 
The study was commenced following approval from the Regional Ethical Committee (REC 
number 12/LO/0422) and institutional Research and Development office. All patients gave 
written informed consent. 
Results 
Patients were divided in two groups according to the development of POAF. 
From the proteomics group of 50 patients, 16 developed POAF and 34 remained in SR. Out of 
those 10 vs. 10 were appropriately matched for age, sex, medications (in particular matching 
them for beta-blockers), cardiovascular risk profile and intraoperative variables (number of 
grafts, cross clamp and cardiopulmonary bypass time) and utilised for 2D-DIGE analysis. 
Furthermore, equally matched 6 vs. 6 were later utilised for Western Blot validation analysis.  
From the gene expression group of 26 patients, 8 developed POAF and 18 remained in SR. 
Two samples were later discarded as RNA deteriorated. All remaining samples (16 vs. 8) 
were then utilised for qPCR analysis.  
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Proteomics 
For the proteomics study, we analysed 10 vs. 10 EAT secretome samples (Table 1). After 2D-
DIGE analysis of the EAT secretome, a total of 35 spots were identified (Figure 1), 
corresponding to 26 differentially expressed proteins (Table 2). Six proteins were found to be 
significantly upregulated in the POAF group. All remaining proteins were downregulated.  
Several proteins of interest, in particular related to inflammation and oxidative stress were 
differentially expressed in the proteomics analysis.  
Amongst those gelsolin was significantly downregulated in the POAF group (p=0.031).  
A protein spot containing selenium binging protein-1 (SBP-1) was differentially expressed in 
the EAT, being upregulated in patients who developed POAF (p = 0.049). Dimethylarginine 
dimethylaminohydrolase 2 (DDAH2) was also differentially expressed in the EAT, being 
increased in the POAF group (p = 0.04).  A protein spot containing catalase was differentially 
expressed in the EAT secretome, being increased in the POAF group (p = 0.004).  
 
Western blotting 
Western blot validation of findings was performed on 6 vs. 6 EAT protein extracts. As a 
loading control a silver stain of a gel containing all selected samples was performed to ensure 
equal amount of proteins was loaded. Western blot analysis of the tissue extracts confirmed a 
significant reduction in gelsolin in the AF group (p<0.001) as shown in Figure 2. Validations 
for the remaining targets did not show statistically significant differences. 
 
 
qPCR 
Gene expression studies were performed via qPCR on 16 vs. 8 samples, controls and POAF 
respectively (Table 3). Gene expression for gelsolin was significantly reduced in the AF 
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group (p=0.038), confirming the proteomics findings (Figure 3). Gene expression for the 
remaining targets did not show statistically significant variations. 
 
Discussion 
The pathogenesis of AF is multifactorial and the mechanisms of it are not yet fully elucidated. 
Iwasaki and colleagues describe the important interaction between initiating triggers, such as 
rapidly firing ectopic in the pulmonary veins and abnormal atrial substrates.6 This can be 
translated in the postoperative setting as a synergistic interaction between surgery-induced 
triggering factors and pre-existing abnormal atrial substrates reaching the ‘AF threshold’. In 
the apparently normal heart, predisposing factors may be subtler.  
Aim of our study was to explore the pre-existing activity of the EAT by analyzing the 
secretome which could act as substrate in the myocardial environment possibly modulating 
the susceptibility to POAF. 
Systemic inflammatory response to cardiac surgery and oxidative stress are important factors 
implicated in the development of POAF.7-8 Gelsolin exerts antinflammatory properties by 
severing actin filaments. DDAH2 degrades nitric oxide synthase inhibitor ADMA 
(asymmetric dimethylarginine), known to increase oxidative stress.  SBP-1 and catalase also 
have anti-oxidant properties.  
Amongst the array of differentially expressed proteins, we believe gelsolin highlights possible 
interesting links between EAT and AF. 
Gelsolin was shown to be downregulated in the POAF group by three independent techniques: 
in the EAT secretome by 2D-DIGE and LC-MS/MS, on the EAT protein extracts by Western 
blot, and at the gene level by qPCR. 
2D-DIGE methodology may reveal changes in protein net expression, as demonstrated for 
gelsolin (consistent changes in 2D gels, Western blot and gene expression), or changes in 
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post-translational modifications, which may not be possible to validate by Western blot 
analysis or gene expression studies. These modifications in fact are generally enzymatic 
covalent addition of functional groups to the protein or cleavage of regulatory subunits taking 
place during or after protein biosynthesis, which increase the functional diversity of the 
proteome.  
 
Inflammation and ion channel regulation: the role of gelsolin 
Anti-inflammatory adipokines secreted by the epicardial fat such as adiponectin have shown 
protective effect against AF following cardiac surgery.2 Lymphomononuclear inﬁltrates and 
ﬁbrosis have also been described in histological sections of atrial tissue of patients with AF.9 
Associations between inflammatory markers such as CRP and interleukin 6 (IL-6) and AF 
have been proposed.10-11 
Ion channel function is involved in the genesis of POAF and in particular the influx of Ca2+ 
through the L-type Ca2+channels, the main current generating the plateau phase of the atrial 
action potential. Van Wagoner et al. described how the L-Type Calcium Current (ICaL) in 
atrial myocytes is increased in patients developing postoperative AF. Triggered activity (e.g. 
delayed afterdepolarizations) may in fact be generated by an increase in Ca2+ influx through 
L-type Ca2+ channels in the cardiomyocyte, potentially initiating AF.12 
Gelsolin is a ubiquitous 82-kD actin-binding protein formed of six homologous subdomains 
(S1-S6). Activated by Ca2+ and acidosis, it changes its conformation exposing actin-binding 
sites. Active form can sever actin filaments or bind actin monomers preventing its 
disorganised assembly. 
Actin exposed or released by damaged cells activates inflammatory mediators such as LPS 
(lysophosphatidic acid) and platelet-activating factor enhancing the inflammatory process.13 
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Gelsolin directly binds and inhibits these mediators and its main function is to scavenge 
proinflammatory actin filaments by severing and capping them,14 thus counteracting 
excessive host response to stress. Recombinant gelsolin administration increased survival in 
experimental sepsis animal models.15-16 Reduced plasma gelsolin was also observed in 
patients with rheumatoid arthritis in combination with the presence of gelsolin-actin 
complexes in the synovial fluid.17 In the context of POAF, gelsolin could be protective as a 
guard against an overwhelming inflammatory state. 
Furthermore, L-type Ca2+ channels are influenced by cytoskeleton structural changes 
mediated by gelsolin, where its increasing concentration inactivates the channels.18 Schrickel 
et al. interestingly described how altered Ca2+ currents associated with gelsolin deficiency 
promote AF in a mouse model.19 As demonstrated by van Wagoner and colleagues, Ca2+ 
current in atrial myocytes is increased in patients developing POAF generating delayed after 
depolarisations substrate for AF.12 Gelsolin deficiency could lead to an increased opening 
probability of these Ca2+ channels leading to increased excitability of the myocardium 
ultimately promoting AF.  
 
Limitations 
There is not enough evidence yet to understand if gelsolin produced in the EAT might act as a 
paracrine mediator onto the myocardium similarly to other actin binding proteins.20 There is 
also an obvious problem of sampling EAT at a single point in time. Further studies are needed 
to understand whether its effects demonstrated on the cardiomyocite may also be exerted by 
the epicardial component. 
 
Conclusion 
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EAT has recently become target of intense research and there is growing evidence of its 
implication in the genesis and maintenance of AF. We analyse for the first time proteomic 
changes in the EAT of patients who are predisposed to develop POAF. Several proteins are 
differentially expressed in the EAT, gelsolin plays an important role in pathways known to be 
involved in the genesis of POAF such as inflammation and ion channel disturbances. 
Improving the understanding of the role of EAT may offer novel insights into the prevention 
and treatment of AF. 
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Figure legends 
Figure 1. A) a representative EAT 2D-DIGE fluorescent image. The proteins expressed in 
POAF are labelled with Cy5 dye (red spot) and those expressed in SR are labelled with Cy3 
dye (green spots). Yellow spots indicate proteins similarly expressed in both groups. B) 
Corresponding silver-stained gel. The x axis represents the isoelectric point (pI) and the y axis 
is the molecular weight (Mw) in kilo Daltons (kD). Identified protein spots were labelled with 
numbers as shown in Table 2. 
 
Figure 2. Western blot validation on EAT protein extracts showing significant gelsolin 
downregulation in POAF. Anti-gelsolin 1:1000, rabbit polyclonal antibody, ab74420, abcam. 
Chart based on mean ± SEM densitometry values. *** = (p<0.001). AU = arbitrary units. SR 
= sinus rhythm. AF = atrial fibrillation. 
 
Figure 3. Column scatter dot plot graph showing gelsolin gene expression significantly 
reduced in AF (p=0.038). Values are CT (cycle threshold for gene amplification) fold change 
against the reference sample. Each dot/square represent one sample value, error bars represent 
mean with SD.  
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Table 1: Baseline characteristics of patients in the secretome proteomics group.  
 
EF = ejection fraction; CCS = Canadian Cardiovascular Society; NYHA = New York Heart 
Association; CPB = cardiopulmonary bypass; X-clamp = cross clamp. Categorical data are 
numbers (%); continues data are means ± SD. p-values for comparisons between patient 
 
Variables POAF 
(n=10) 
SR 
(n=10) 
p value 
Age 69.8 +/-5.7 67.6 +/- 6.4 0.43 
Gender (male) 9 (90%) 9 (90%) 1 
Hypertension 9 (90%) 7 (70%) 0.58 
Diabetes 4 (30%) 3 (40%) 1 
EF < 40 % 1 1 1 
e-GFR < 60 1 (10%) 2 (20%) 1 
Beta blockers pre-op 7 (70%) 7 (70%) 1 
Beta blockers post-op 7 (70%) 10 (100%) 0.21 
CCS 3-4 0 0 N/A 
NYHA III-IV 0 1 (10%) 0.33 
Grafts n. 3.3 +/- 0.8 3.4 +/- 0.5 0.75 
CPB time 74.4 +/- 31.5 75.4 +/- 14.2 0.93 
X-clamp time 44.7 +/- 15.8 48.7 +/- 14.2 0.58 
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Table 2: H
um
an E
A
T
 secretom
e proteins identiﬁed by 2D
-D
IG
E and M
S/M
S (PO
A
F vs. SR
). 
Spot no. 
Protein name 
 
UniProt ID 
Theoretical 
Number 
of unique 
peptides 
Number 
of unique 
spectra 
Number 
of total 
spectra 
%
 
sequence 
coverage 
Av. 
Ratio 
p Value 
M
w 
(Da) 
pI 
1 
A
polipoprotein A
-II 
A
PO
A
2_H
U
M
A
N
 
11,175 
6.27 
2 
3 
6 
21.00%
 
-1.66 
0.0087 
2 
A
polipoprotein A
-II 
A
PO
A
2_H
U
M
A
N
 
11,175 
6.27 
2 
3 
5 
21.00%
 
-1.24 
0.034 
3 
Transthyretin 
TTH
Y
_H
U
M
A
N
 
15,887 
5.49 
4 
6 
9 
34.00%
 
-1.4 
0.019 
4 
C
oactosin-like protein 
C
O
TL1_H
U
M
A
N
 
15,945 
5.5 
3 
3 
4 
16.90%
 
-1.32 
0.016 
4 
Transthyretin 
TTH
Y
_H
U
M
A
N
 
15,887 
5.49 
6 
7 
10 
34.70%
 
-1.32 
0.016 
5 
U
biquitin-conjugating enzym
e E2 N
 
U
B
E2N
_H
U
M
A
N
 
17,138 
6.13 
4 
5 
9 
26.30%
 
-1.57 
0.003 
5 
Transthyretin 
TTH
Y
_H
U
M
A
N
 
15,887 
5.49 
8 
9 
12 
49.70%
 
-1.57 
0.003 
6 
Transthyretin 
TTH
Y
_H
U
M
A
N
 
15,887 
5.49 
3 
5 
7 
18.40%
 
-1.53 
0.0037 
6 
Prefoldin subunit 5 
PFD
5_H
U
M
A
N
 
17,328 
5.94 
3 
3 
5 
24.70%
 
-1.53 
0.0037 
7 
Transthyretin 
TTH
Y
_H
U
M
A
N
 
15,887 
5.49 
3 
4 
6 
18.40%
 
-1.36 
0.0051 
8 
A
polipoprotein A
-I  
A
PO
A
1_H
U
M
A
N
 
30,779 
5.56 
27 
32 
51 
80.10%
 
-1.38 
0.037 
9 
A
polipoprotein A
-I  
A
PO
A
1_H
U
M
A
N
 
30,779 
5.56 
17 
22 
34 
62.50%
 
-1.28 
0.013 
10 
A
polipoprotein A
-I  
A
PO
A
1_H
U
M
A
N
 
30,779 
5.56 
12 
15 
27 
40.80%
 
-1.41 
0.019 
10 
Prelam
in-A
/C
 
LM
N
A
_H
U
M
A
N
 
74,141 
6.57 
15 
16 
29 
17.80%
 
-1.41 
0.019 
11 
N
(G
),N
(G
)-dim
ethylarginine 
D
D
A
H
2_H
U
M
A
N
 
29,644 
5.66 
12 
17 
30 
55.80%
 
1.47 
0.044 
 
20 
Spot no. 
Protein name 
 
UniProt ID 
Theoretical 
Number 
of unique 
peptides 
Number 
of unique 
spectra 
Number 
of total 
spectra 
%
 
sequence 
coverage 
Av. 
Ratio 
p Value 
M
w 
(Da) 
pI 
dim
ethylam
inohydrolase 2 
12 
A
nnexin A
4  
A
N
X
A
4_H
U
M
A
N
 
35,884 
5.83 
10 
10 
14 
32.90%
 
-1.25 
0.046 
13 
Isochorism
atase dom
ain-containing protein 1 
ISO
C
1_H
U
M
A
N
 
32,237 
6.96 
3 
4 
7 
13.40%
 
1.47 
0.011 
14 
A
ctin-related protein 2/3 com
plex subunit 2 
A
R
PC
2_H
U
M
A
N
 
34,334 
6.84 
4 
4 
7 
12.70%
 
1.39 
0.039 
14 
Ig gam
m
a-1 chain C
 region 
IG
H
G
1_H
U
M
A
N
 
36,105 
8.46 
4 
5 
9 
16.40%
 
1.39 
0.039 
15 
Pigm
ent epithelium
-derived factor 
PED
F_H
U
M
A
N
 
46,314 
5.97 
4 
4 
4 
10.30%
 
-1.24 
0.036 
15 
Prelam
in-A
/C
 
LM
N
A
_H
U
M
A
N
 
74,141 
6.57 
7 
7 
10 
11.40%
 
-1.24 
0.036 
15 
V
im
entin 
V
IM
E_H
U
M
A
N
 
53,653 
5.05 
4 
4 
6 
9.66%
 
-1.24 
0.036 
16 
A
lpha-1-antitrypsin  
A
1A
T_H
U
M
A
N
 
46,738 
5.37 
8 
9 
15 
20.60%
 
-1.42 
0.024 
16 
A
lpha-2-H
S-glycoprotein 
FETU
A
_H
U
M
A
N
 
39,323 
5.43 
10 
14 
23 
27.80%
 
-1.42 
0.024 
17 
A
lpha-2-H
S-glycoprotein 
FETU
A
_H
U
M
A
N
 
39,323 
5.43 
8 
11 
19 
27.80%
 
-1.4 
0.028 
17 
A
lpha-1-antitrypsin 
A
1A
T_H
U
M
A
N
 
46,738 
5.37 
8 
9 
14 
18.90%
 
-1.4 
0.028 
17 
A
lpha-1-antichym
otrypsin  
A
A
C
T_H
U
M
A
N
 
47,653 
5.33 
3 
3 
5 
6.86%
 
-1.4 
0.028 
17 
V
im
entin 
V
IM
E_H
U
M
A
N
 
53,653 
5.05 
15 
15 
25 
31.80%
 
-1.4 
0.028 
18 
V
itam
in D
-binding protein 
V
TD
B
_H
U
M
A
N
 
52,965 
5.4 
11 
13 
24 
32.90%
 
-1.28 
0.022 
18 
A
ntithrom
bin-III  
A
N
T3_H
U
M
A
N
 
52,604 
6.32 
18 
23 
43 
40.90%
 
-1.28 
0.022 
19 
A
ntithrom
bin-III  
A
N
T3_H
U
M
A
N
 
52,604 
6.32 
15 
21 
35 
37.70%
 
-1.32 
0.012 
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19 
60 kD
a heat shock protein, m
itochondrial 
C
H
60_H
U
M
A
N
 
61,056 
5.7 
16 
18 
28 
37.20%
 
-1.32 
0.012 
19 
V
itam
in D
-binding protein 
V
TD
B
_H
U
M
A
N
 
52,965 
5.4 
9 
9 
16 
28.50%
 
-1.32 
0.012 
20 
Selenium
-binding protein 1 
SB
P1_H
U
M
A
N
 
52,392 
5.93 
25 
32 
56 
52.30%
 
1.3 
0.05 
21 
Selenium
-binding protein 1 
SB
P1_H
U
M
A
N
 
52,392 
5.93 
26 
37 
64 
54.00%
 
1.36 
0.049 
22 
A
lpha-enolase 
EN
O
A
_H
U
M
A
N
 
47,170 
7.01 
9 
9 
15 
26.50%
 
-1.3 
0.023 
23 
Prelam
in-A
/C
 
LM
N
A
_H
U
M
A
N
 
74,141 
6.57 
13 
14 
25 
21.80%
 
-1.42 
0.031 
24 
B
eta-2-glycoprotein 1  
A
PO
H
_H
U
M
A
N
 
38,299 
8.34 
3 
3 
4 
16.20%
 
-1.3 
0.0025 
24 
Ig gam
m
a-1 chain C
 region 
IG
H
G
4_H
U
M
A
N
 
35,940 
7.18 
2 
2 
3 
16.20%
 
-1.3 
0.0025 
25 
C
atalase 
C
A
TA
_H
U
M
A
N
 
59,757 
6.9 
16 
16 
29 
32.40%
 
1.28 
0.004 
26 
C
atalase 
C
A
TA
_H
U
M
A
N
 
59,757 
6.9 
21 
24 
35 
40.20%
 
1.23 
0.01 
27 
G
elsolin 
G
ELS_H
U
M
A
N
 
85,698 
5.9 
19 
27 
42 
34.70%
 
-1.25 
0.042 
28 
G
elsolin 
G
ELS_H
U
M
A
N
 
85,698 
5.9 
8 
10 
17 
13.00%
 
-1.3 
0.031 
28 
Serotransferrin 
TR
FE_H
U
M
A
N
 
77,064 
6.81 
7 
7 
12 
12.90%
 
-1.3 
0.031 
29 
Serotransferrin 
TR
FE_H
U
M
A
N
 
77,064 
6.81 
21 
23 
36 
31.10%
 
-1.27 
0.05 
30 
Serotransferrin 
TR
FE_H
U
M
A
N
 
77,064 
6.81 
29 
34 
58 
42.80%
 
-1.28 
0.047 
31 
Serotransferrin 
TR
FE_H
U
M
A
N
 
77,064 
6.81 
39 
50 
86 
52.90%
 
-1.32 
0.028 
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32 
Serotransferrin 
TR
FE_H
U
M
A
N
 
77,064 
6.81 
31 
40 
68 
47.90%
 
-1.37 
0.023 
33 
Serotransferrin 
TR
FE_H
U
M
A
N
 
77,064 
6.81 
40 
51 
79 
53.30%
 
-1.31 
0.023 
34 
Serotransferrin 
TR
FE_H
U
M
A
N
 
77,064 
6.81 
44 
61 
109 
54.60%
 
-1.29 
0.021 
35 
Serotransferrin 
TR
FE_H
U
M
A
N
 
77,064 
6.81 
52 
67 
112 
67.20%
 
-1.21 
0.042 
U
iniProt ID
 = protein identifier w
ithin U
niversal Protein R
esource (U
niProt) know
ledgebase; M
W
 = m
olecular w
eight; D
a = D
altons; pI = isoelectric point; N
um
ber of unique 
peptides =  peptides on w
hich protein identification w
as based; N
um
ber of unique spectra = spectra that m
atched different peptides (even if the peptides overlap) or m
atch 2 
different charge states of the sam
e peptide, or m
atch both a peptide and a m
odified form
 of the peptide; N
um
ber of total spectra = sum
 of spectra identified in each protein; %
 
sequence coverage = percentage of sequence of the full-length protein covered by the unique peptides that w
ere identified. 
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Table 3: qPCR delta CT fold change against the reference sample.  
SR 
Sample 
ΔcT 
  
POAF 
Sample 
ΔcT 
  
1 1.000 17 0.933 
2 3.639 18 1.508 
3 2.510 19 0.323 
4 2.538 20 1.832 
5 3.513 21 1.570 
6 0.958 22 2.862 
7 1.380 23 1.848 
8 3.409 24 2.376 
9 2.336   
10 4.474   
11 2.558   
12 4.253   
13 3.625   
14 3.030   
15 0.672   
16 2.899   
 2.675 p value 
0.0380 
1.656 
Gene expression for gelsolin shows significant reduction in the POAF group 
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